1. Scrip
  2. >>Therapy Areas

Predictable AbbVie has good Humira-driven first quarter

 
• By Mandy Jackson

For AbbVie, boring is good. The company's first quarterly earnings report since its split from Abbott met or slightly beat consensus expectations as Humira continued to drive revenue growth with a 16% year-over-year sales bump.

For AbbVie, boring is good. The company's first quarterly earnings report since its split from Abbott met or slightly beat consensus expectations as Humira continued to drive revenue growth with a 16% year-over-year sales bump.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapeutic Category

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.